Skip to main content

Table 4 Effect of β-mannanase on pig serum glucose, insulin, acute phase protein, and cytokine concentrationsa,b

From: Lipopolysaccharide immune stimulation but not β-mannanase supplementation affects maintenance energy requirements in young weaned pigs

Treatment

Control dietc

Enzyme dietd

Contrast P-value

Estimate

SEM

Estimate

SEM

Glucose, mmol/L

7.70

0.46

7.41

0.25

0.585

Insulin, pmol/L

88.92

10.99

83.35

6.06

0.664

Insulin:Glucose

11.56

1.21

11.08

0.67

0.734

Acute phase protein, mg/mL

 Haptoglobin

1.57

0.22

1.02

0.14

0.050

 MBLe

125.4

8.6

117.5

5.2

0.445

Cytokine, pg/mLf

 GM-CSF

17.01

13.01

14.56

7.85

0.874

 IL-1α

35.01

6.81

7.50

4.27

0.004

 IL-1β

1064

598

1138

361

0.917

 IL-1ra

428.6

257.5

673.7

161.5

0.435

 IL-2

328.4

157.6

228.8

95.0

0.596

 IL-4

995.5

545.6

711.6

329.0

0.662

 IL-6

190.2

61.5

98.72

38.59

0.230

 IL-8

263.1

95.4

402.2

57.5

0.230

 IL-10

499.4

159.1

332.9

95.9

0.383

 IL-12

1570

173

1730

104

0.439

 IL-18

1994

546

1380

329

0.350

 TNFα

24.29

39.90

52.30

25.02

0.563

  1. aBlood was collected on d 8 of the experiment 6 h post-feeding, prior to the immune challenge beginning on d 10
  2. bn = 10 pigs per treatment
  3. cControl diet was a corn, soybean mean, and soy hulls based diet containing 1.33% β-mannans, and did not contain β-mannanase enzyme. Pigs on the control (CON) treatment were fed the control diet and estimates are representative of the CON treatment only
  4. dEnzyme diet was the control diet supplemented with 0.056% β-mannanase (Hemicell™ HT-D, Elanco Animal Health, Guelph, ON, Canada; endo-1,4-β-mannanase (160 × 106 units/kg) from Paenibacillus alvei). Pigs on the enzyme (ENZ) and immune system stimulation (ISS) treatments were fed the enzyme diet. Estimates are representative of the ENZ and ISS treatments prior to immune stimulation
  5. eMannose binding lectin A (MBL)
  6. fGranulocyte-macrophage colony-stimulating factor (GM-CSF); interleukin-1α (IL-1α); interleukin-1β (IL-1β); interleukin-1 receptor antagonist (IL-1ra); interleukin-2 (IL-2); interleukin-4 (IL-4); interleukin-6 (IL-6); interleukin-8 (IL-8); interleukin-10 (IL-10); interleukin-12 (IL-12); interleukin-18 (IL-18); tumor necrosis factor alpha (TNFα)